Drug
Gp2013 A Proposed Biosimilar Rituximab
Gp2013 A Proposed Biosimilar Rituximab: highest development phase Phase 3, developed by Sandoz. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sandoz
Trials
| Drug | Phase | Indication |
|---|---|---|
| GP2013 - A Proposed biosimilar rituximab NCT02514772 | Phase 3 | Rheumatoid Arthritis |
Latest
No recent events.
Follow Gp2013 A Proposed Biosimilar Rituximab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.